Aevi Genomic Medicine

What Aevi Genomic Medicine does

Aevi Genomic Medicine is a publicly traded (NASDAQ: GNMX) clinical-stage biopharmaceutical company founded in 2000 and headquartered in Wayne, United States. Per the company's own description, it focuses on translating genetic discoveries into novel therapies, with an operating emphasis on rare and neurodevelopmental disease given its 2015 acquisition of neuroFix Therapeutics and its translational research partnership with The Children's Hospital of Philadelphia, which led a $28M financing round in October 2017.

The company is small (11-50 employees) and has funded operations almost entirely through equity capital rather than product revenue. Across nine disclosed financing rounds since 2001, Aevi has raised approximately $78.5M in aggregate, with investors historically including Alta Berkeley Venture Partners, Alta Partners, and Koor Corporate Venture Capital, and most recently an undisclosed lead in a $4.9M round on 2018-08-21. Leadership consists of Michael F. Cola as President & CEO and John Leaman as CFO.

The business model is preclinical/clinical-development oriented: Aevi monetizes its pipeline through eventual commercialization, licensing, or partnership transactions rather than current product sales. Its go-to-market therefore depends on progressing therapeutic candidates through clinical milestones to attract either a strategic acquirer or commercialization partner. No pricing, distribution, customer segment, or marketing channel information is disclosed in the input data, consistent with a pre-commercial biotech.

Name

Aevi Genomic Medicine

Website

https://aevigenomics.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Genomic Medicine Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

akta.pro secondary industries

Neurology/CNS Gene Therapies (HLAAACAH), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Genomic medicine
• Rare disease therapeutics
• Novel therapy development
• Pediatric neurology treatments
• Clinical-stage biotech

Headquarters

HQ city

Wayne

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies, targeting rare and orphan diseases with a particular emphasis on neurological and neurodevelopmental disorders. The company is a clinical-stage biotechnology firm developing pharmaceutical treatments based on genomic insights.

Differentiator

Problem solved

Functional benefit

Products and services

• Genomic-based novel therapies

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Direct peers

• Audentes Therapeutics: Audentes developed AAV-based gene therapies for rare neuromuscular diseases, a genetic-medicine orientation that mirrors Aevi's stated mission before its acquisition by Astellas.
• Ultragenyx Pharmaceutical: Ultragenyx develops therapeutics for rare and ultra-rare genetic diseases, with multiple programs in metabolic, CNS, and other genetically defined indications — closely paralleling Aevi's focus on genetically driven therapeutics.
• REGENXBIO: REGENXBIO is a clinical-stage gene therapy company developing AAV-based treatments, with CNS and rare-disease programs that overlap directly with the genomic-medicine and neuroFix-related therapeutic areas Aevi has pursued.
• Spark Therapeutics: Spark Therapeutics pioneered AAV-based gene therapies for genetic diseases, including a CNS-directed program, making it a direct historical peer in the genomic-medicine space where Aevi operates.
• Voyager Therapeutics: Voyager focuses on gene therapies for neurological diseases, making it highly comparable to the CNS/neuroFix-related direction Aevi signaled through its 2015 acquisition.
• Neuralstem: Neuralstem is a small clinical-stage biopharmaceutical company developing treatments for CNS and rare neurological conditions, comparable in scale and therapeutic focus to Aevi's neuroFix-related pipeline direction.
• Medgenics: Medgenics is a small-cap public biotech developing therapies for rare and orphan diseases, a comparable profile to Aevi as a sub-scale public genomic-medicine company.
• Dimension Therapeutics: Dimension Therapeutics was a clinical-stage rare-disease gene therapy company targeting genetic diseases including CNS indications, structurally comparable to Aevi's genomic-medicine positioning before its acquisition by Ultragenyx.

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is an established rare-disease therapeutics developer with a focus on genetic and genomic diseases, directly comparable to Aevi's stated mission of translating genetic discoveries into therapies for underserved patient populations.

Others

• Children's Hospital of Philadelphia (CHOP) Research Institute: CHOP is the lead investor from Aevi's 2017 financing round and operates a major pediatric genomic-medicine research program; it is thematically related as a discovery engine and partner in the rare-disease therapeutics pipeline.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds9 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aevi Genomic Medicine